Difficulty: Hard

Average Score: 40%

Therapeutic duplication would be a concern for a patient prescribed both:

Rationale

Ventolin HFA and Xopenex HFA are both short-acting beta-agonists used for asthma relief.

Both medications serve the same therapeutic purpose of providing quick relief from acute asthma symptoms by acting as bronchodilators. Their overlapping mechanisms of action can lead to therapeutic duplication if prescribed concurrently, which may increase the risk of adverse effects without additional benefits.

A (Spiriva Respimat and Dulera) YOUR ANSWER

Spiriva Respimat is a long-acting anticholinergic, while Dulera is a combination inhaler containing a long-acting beta-agonist and a corticosteroid. Since they represent different classes of medications with distinct mechanisms, there is no therapeutic duplication when these two are prescribed together.

B (Flovent HFA and Incruse Ellipta) YOUR ANSWER

Flovent HFA is an inhaled corticosteroid, while Incruse Ellipta is a long-acting anticholinergic. These medications target different pathways in asthma management, thus they do not duplicate therapy when used together.

D (Serevent Diskus and Atrovent HFA) YOUR ANSWER

Serevent Diskus is a long-acting beta-agonist, and Atrovent HFA is a short-acting anticholinergic. While both are used for asthma management, they work through different mechanisms, preventing therapeutic duplication.

Conclusion

Therapeutic duplication occurs when two medications with similar effects are prescribed together, which can lead to unnecessary side effects and complications. In this case, the concurrent use of Ventolin HFA and Xopenex HFA exemplifies this concern, as both medications are short-acting beta-agonists intended for immediate asthma relief. Awareness of such overlaps is crucial in medication management to ensure patient safety and effective treatment outcomes.

Related Questions

View all